Atara Biotherapeutics 2023 JPMorgan Healthcare Conference

Atara Biotherapeutics presented its allogeneic T-cell immunotherapy pipeline at the 41st JPMorgan Healthcare Conference in January 2023. The company highlighted Ebvallo (tab-cel), the first regulatory-approved allogeneic T-cell therapy, and discussed ATA188 for multiple sclerosis and next-generation CAR T programs targeting EBV-positive diseases.